Currently in clinical development
A new innovative product has been developed. It exhibits a pronounced antiphthisic activity against mycobacteria, both virulent strains of M. tuberculosis and resistant to first-line treatments.
As well, it exhibits a bacteriostatic effect.
As expected, it blocks a specific bacterial enzyme, leading to impaired ATP synthesis in a M. tuberculosis cell. The active component is primarily metabolized via cytochrome P450 enzymes.
This drug product is currently in clinical development.